Azilsartan medoxomil capsule and preparation method thereof

Abstract

The invention relates to an azilsartan medoxomil capsule and a preparation method thereof. The capsule is prepared from raw materials in parts by mass as follows: 10-30 parts of azilsartan medoxomil, 30-70 parts of lactose, 20-50 parts of microcrystalline cellulose, 5-15 parts of crospovidone, 1-3 parts of magnesium stearate and 1-3 parts of silicon dioxide. According to the azilsartan medoxomil capsule and the preparation method thereof, pharmaceutical composition for treating hypertension is reasonably proportioned, can rapidly release medicine and can realize a good curative effect on symptoms of diseases.

Description

technical field [0001] The invention relates to an azilsartan medoxomil potassium salt capsule and a preparation method thereof, belonging to the technical field of medicine. Background technique [0002] Azilsartan medoxomil was developed by Takeda, Japan. A prodrug of azilsartan that is hydrolyzed to azilsartan during absorption from the gastrointestinal tract. It was approved for marketing by FDA on February 22, 2011. The trade name is Edarbi, and the specifications are 40mg and 80mg. In April 2012, Azilsartan was launched in Japan, trade name: Azilva, specification: 20mg, 40mg. Azilsartan medoxomil is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan selectively blocks the binding of angiotensin II to the AT1 receptor (the affinity of azilsartan to the AT1 receptor is more than 10,000 times higher than that of the AT2 receptor), thereby blocking the vasoconstriction caused by angiotensin II , Aldosterone secretion and other blood pressure effects...

AI Technical Summary

Problems solved by technology

Although some of the current emerging antihypertensive drugs have certain potential, their own shortcomings in effectiveness, safety and tolerability, and / or administration methods may prevent them from replacing Edarbi